The Center for Biosimilars—May 2, 2018
The Center for Biosimilars interviewed HSS rheumatologist Anne R. Bass, MD, who explained why patients with rheumatic conditions are more likely to experience thromboembolic events.
"When patients have rheumatic diseases...they’re at higher risk for blood clotting," said Dr. Bass.
"It’s really been shown to be the case with any rheumatic disease, including rheumatoid arthritis, for example, where the risk is about 2 and a half times when your disease is active than it would be if you didn’t have rheumatoid arthritis," she noted.
Watch the full video at centerforbiosimilars.com.